Haleon shares crater as soft flu demand hits takings Retail Shares in Haleon slumped after soft demand for cough, cold and flu medicines forced the consumer healthcare giant to cut its revenue target. The FTSE 100 firm lost more than 11 per cent in early trading, to 333p. Haleon had been expecting revenue growth of between three and five per cent but on Thursday trimmed [...]
Regulator wins decade-long pricing tussle with Pfizer Legal The UK competition watchdog has won permission to appeal in a case against US pharmaceutical giant Pfizer after a long-running legal battle over allegations of excessive pricing, overturning a previous decision by the Tribunal. The court said the Competition Appeal Tribunal (CAT), was “wrong to set aside the [Competition and Market’s Authority’s] decision” in relation to [...]
GSK shares slip after buying US cancer treatment firm Nuvalent for $10.6bn Pharma Pharma giant GSK has sealed a $10bn deal to snap up Boston-based biopharmaceutical company Nuvalent. The FTSE 100 titan said it will pay $124 per share in cash in the agreement, marking a 40 per cent premium over what Nuvalent’s stock was trading at just before this announcement. The deal is expected to officially close [...]
Haleon takes hit from ‘weak cold and flu season’ but Sensodyne shines April 29, 2026 After being spun out from GSK in the biggest London IPO in decades, City analyst are looking for more from the emblematic FTSE 100 consumer healthcare powerhouse with roots in a Lombard Street apothecary shop Fewer sniffles during the winter have sent a chill through sales volumes at Haleon, the FTSE 100 over-the-counter remedy maker. [...]
Reckitt: Durex condom maker strips back costs as profit inches up March 5, 2026 Consumer goods giant Reckitt posted a bump to revenue in the last financial year as its cost overhaul strategy to focus on specific divisions ramped up. The blue-chip firm – which owns a massive portfolio of brands including Dettol, Durex, Lysol, Finish, Vanish, and Gaviscon – recorded a 5.2 per cent increase in revenue, driven [...]
Astrazeneca: FTSE 100 giant shrugs off China worries with profit upgrade November 12, 2024 Pharmaceuticals giant Astrazeneca has reported double-digit sales growth on higher demand and said it remains committed to China despite the detention of a high-ranking staff member there. The FTSE 100 firm told markets this morning that total revenue rose 19 per cent to $39.2bn (£30.6bn) in the first nine months of the year. The London-listed [...]
GSK: Zantac settlements hit profit but guidance unchanged October 30, 2024 Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and said its core outlook remained unchanged. Operating profit fell by 86 per cent, and earnings per share slumped due to a settlement charge of £1.8bn related to the Zantac lawsuits. The lawsuits arose [...]
Advanced Medical Solutions: Strong US sales boosts revenue for wound-closure tech firm July 15, 2024 Advanced Medical Solutions (AMS) has announced a 10 per cent revenue hike for the first half of 2024 after sales for wound-closure tech in the United States took off. The company, which develops and manufactures tissue-healing technology, announced first-half revenue of £68m. Based on these numbers, the firm said it expected to report adjusted profit [...]
Losses widen for Cohens Chemist amid funding uncertainty May 23, 2024 The company behind Cohens Chemist almost doubled its losses this year, with product shortages and inflation continuing to put pressure on the group.
Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions May 21, 2024 Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.